Cabaletta reports deepened rese-cel responses: 3 SLE patients in DORIS remission, LN complete renal response

Cabaletta Bio, Inc.

3 of 4 non-renal SLE patients achieved DORIS remission; first LN patient achieved complete renal response; all off immunosuppressants and steroids.
First adult dermatomyositis patient maintained major TIS improvement at 3 months, off immunosuppressants and tapering steroids.
Safety: 90% had no CRS or Grade 1 CRS; 90% had no ICANS across first 10 patients dosed with rese-cel.
Deep B cell depletion within first month; repopulation with naïve phenotype starting ~2 months post-infusion; tissue depletion confirmed by lymph node biopsy.
50 clinical sites recruiting in US/Europe; 26 patients enrolled across RESET program as of Feb 13, 2025; average 1 patient/week since November.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.